Clinical Trial Search

Primary: Proportion of Patients Receiving Antibiotics or a Prescription for Antibiotics in the ED — 20; 33 Participants

Primary: Number of Subjects With an Investigator Assessment of Clinical Outcome (Success/Failure) at End of Study — 275; 133 participants

Primary: Total Symptoms Score (TSS) — 0.503; 0.843 scores

Primary: Health Related Quality of Life Score — 91.5; 90.2 scores on a scale — p=0.008

Primary: Host Response to RSV Challenge Measured as Change From Baseline of Chemical Mediators in Nasal Fluid — 23 Participants

Primary: Satisfaction With Time to Receive Result — 180; 53; 3; 72 participants

Primary: Summary Scores on the SUM8 Daily Cough and Phlegm Diary Card On the Morning of Day 4 — 12.96; 12.87; 12.71 units on a scale

Primary: Frequency of ILI(Influenza Like Illness) — 12; 22 participants

Primary: Local Leukotriene Levels — 440; 368; 440; 619 pg/ml

Primary: Occurrences of Pneumonia — 4; 3 Participants

Primary: Mean Estimated Number of Acute Exacerbation of COPD (AECOPD) — 3.04 AECOPD/subject/year

Primary: Antibiotic Sparing — 89; 121 Participants — p=0.025

Primary: Lung Function — 0.071; -3.179; 0.186; -3.345 Z score — p=0.0020

Primary: Nasal Interferon (IFN)-a2 — 10; 26 pg/ml — p=0.04

Primary: Number of Solicited and Unsolicited Adverse Events (AEs) — 17 adverse events

Primary: Average Duration of Fever. — 3.1; 3.6 days — p=0.0174

Primary: Change in Symptom Scores Induced by the Rhinovirus Using Jackson Criteria Including Nasal Congestion, Drainage, Cough, Wheezing — 5.0; 4.2; 2.8 score on a scale

Primary: Circulating RI-001 Titer — 9.24; 4.85; 1.42 Fold Change

Primary: Change in the Total Score of the Investigator's Symptomatic Severity Assessment (Day 0, Day 14) — -4.37; -3.56 score on a scale

Primary: Participants With Detectable RSV Shedding in Nasopharyngeal Wash — 2; 4 Participants

Primary: Airway Symptom Scores Experienced by Subjects During the 1st 4 Days of the Infection — 8.72; 2.77 units on a scale — p=0.049

Primary: Mean Asthma Symptom Score — 2.3; 2.1 Asthma symptom score

Primary: Number of Patients With Adverse Events (AEs) — 27 participants

Primary: Total Symptom Score — 29.25; 17.50; 11.00; 13.00 score on a scale

Primary: Control Status of Patients With Rhinosinusitis — 19.5; 36.8; 43.7 percentage of participants

Primary: The Number of Sampling Visits on Which Participants Are Willing to Undergo Nasosorption and/or NPA Sampling — 124; 60; 0; 0 Sampling visits

Primary: Total Symptom Score (TSS) Area Under the Curve (AUC) — 93.64; 62.53; 73.75; 78.34 days x Score

Primary: Incidence Rates of First Episode of Respiratory Syncytial Virus (RSV) Respiratory Tract Infection (RTI) [Period 1] — 7.93 Cases per 100 person-years

Primary: Detection of Respiratory Viruses — 83 participants

Primary: Antimicrobial Activity by Airway Surface Liquid (ASL) as Measured by Relative Light Units (RLU) — -581; -485 Relative Light Units (RLU)